Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
VISEN Pharmaceuticals logo — Achieve better treatment processes and outcomes by combining...

VISEN Pharmaceuticals

Achieve better treatment processes and outcomes by combining global expertise and strength in endocrine therapies

Founded 2018 China China 42 employees Series B Total: $190.00M Biotechnology, Life Sciences +1

General Information

Company Name VISEN Pharmaceuticals
Founded Year 2018
Location China China
Founders / Decision Makers
Team member
Employees 42
Industries Biotechnology, Life Sciences, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with VISEN Pharmaceuticals. To contact VISEN Pharmaceuticals, visit visenpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does VISEN Pharmaceuticals compare?

A PDF of VISEN Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting VISEN Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About VISEN Pharmaceuticals

Visen Pharmaceuticals is an innovative biopharmaceutical company dedicated to providing innovative therapies and compassionate, patient-centric care for endocrine diseases. Their focus on endocrine diseases in adults and children, and rare endocrine diseases reflects their commitment to addressing diverse patient needs. The company's global expertise and strength in endocrine therapies is exemplified by their team of seasoned professionals with multinational pharmaceutical experiences and their leveraging of cutting-edge technologies and leading resources across the world. Establishing themselves firmly in the Chinese market, with offices in Shanghai, Beijing, Hong Kong, and Taipei, and a state-of-the-art R&D and manufacturing site in Suzhou, reflects their commitment to enhancing R&D, manufacturing, and commercialization efforts. This positioning aims to enable Chinese endocrine patients to benefit from advanced treatment solutions earlier, reflecting a patient-centric approach. In 2018, Visen Pharmaceuticals was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (with participation by Sofinnova Ventures), to develop and commercialize Ascendis Pharma's endocrinology therapies in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. Their recent $150 million Series B financing led by Sequoia China in January 2021 with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, alongside existing investors, including Ascendis Pharma A/S, Vivo Capital, and Sofinnova Investments, signifies a strong vote of confidence from the investor community. This substantial investment underlines the potential and progress of Visen Pharmaceuticals in advancing endocrine therapies and expanding their impact in Greater China.

Business keywords: biopharmaceutical, endocrine therapies, patient-centric care, R&D, pharmaceutical, investment, Series B financing, innovation, treatment processes, multinational, China market, Ascendis Pharma A/S, VIVO Capital

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $150.00M 10
HBM Healthcare Investments OrbiMed Sofinnova Investments
HBM Healthcare Investments, OrbiMed +8
08 Jan 2021
Series A $40.00M -
13 Nov 2018

VISEN Pharmaceuticals Alternatives & Competitors

View All Alternatives
VISEN Pharmaceuticals vs
Spruce Biosciences
Spruce Biosciences United States

Advancing Treatments for Congenital Adrenal Hyperplasia and Other Rare Endocrine Disorders

Post-IPO Equity
27 employees
Biopharma, Biotechnology
Compare VISEN Pharmaceuticals vs Spruce Biosciences
VISEN Pharmaceuticals vs
Reistone Biopharma
Reistone Biopharma China

Focusing on rapidly developing innovative medicines through global collaborations within Research an...

Series A
52 employees
Biotechnology, Pharmaceutical
Compare VISEN Pharmaceuticals vs Reistone Biopharma
VISEN Pharmaceuticals vs
Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. United States

Inspired by patients and families around the world, we are advancing much needed therapies for rare...

Post-IPO Equity
88 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About VISEN Pharmaceuticals

Achieve better treatment processes and outcomes by combining global expertise and strength in endocrine therapies
VISEN Pharmaceuticals was founded in 2018.
VISEN Pharmaceuticals is headquartered in China.
VISEN Pharmaceuticals operates in Biotechnology, Life Sciences and Pharmaceutical. Its work centres on biopharmaceutical, endocrine therapies, patient-centric care and R&D.
VISEN Pharmaceuticals has approximately 42 employees.
VISEN Pharmaceuticals has completed 2 funding rounds, raising a total of $190.00M. The latest funding stage is Series B.
Top alternatives and competitors to VISEN Pharmaceuticals include Spruce Biosciences, Reistone Biopharma, Soleno Therapeutics, Inc., Biohaven, CaSRevolution. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VISEN Pharmaceuticals and Spruce Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for VISEN Pharmaceuticals, https://bouncewatch.com/company/visen-pharmaceuticals, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout